Skip to Main Content

Author Details

John C Lieske
Mayo Clinic
1992
346
63
PMIDPaper TitleJournal TitlePublished Year
37458799Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.Pediatr Nephrol2024
36007597PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.Kidney Int2023
38025210Assessing GFR With Proenkephalin.Kidney Int Rep2023
37795587Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.Kidney Int2023
35843439Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.Am J Kidney Dis2023
37259709Estimating glomerular filtration rate with new equations: can one size ever fit all?Crit Rev Clin Lab Sci2023
37259199Authors' Reply: Urine Metabolomic Versus Standard Chemistry Analysis: What can Metabolomic Analysis Bring to the Treatment and Prevention of Urolithiasis?J Am Soc Nephrol2023
37019509Mendelian Randomization: A Powerful Tool to Illuminate Pathophysiologic Mechanisms.Mayo Clin Proc2023
37184480Outpatient Antibiotic Use is Not Associated with an Increased Risk of First-Time Symptomatic Kidney Stones.J Am Soc Nephrol2023
37118061Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).Urolithiasis2023
37284679The Site and Type of <i>CLCN5</i> Genetic Variation Impact the Resulting Dent Disease-1 Phenotype.Kidney Int Rep2023
37342976End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.Clin J Am Soc Nephrol2023
37441487Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant.Kidney Int Rep2023
37273015Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).Urolithiasis2023
37370648Performance of Nuclear Magnetic Resonance-Based Estimated Glomerular Filtration Rate in a Real-World Setting.Bioengineering (Basel)2023
37103512Reply by Authors.Urol Pract2023
37103500Non-race-based Glomerular Filtration Rates to Estimate Renal Functional Outcomes Following Radical and Partial Nephrectomy.Urol Pract2023
37003973Impact of race-independent equations on estimating glomerular filtration rate for the assessment of kidney dysfunction in liver disease.BMC Nephrol2023
36888987Tissue Inhibitor Metalloproteinase-2 and Insulin-Like Growth Factor Binding Protein-7 Kinetics Following Exposure to High-Dose Methotrexate.Kidney3602023
36888927Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.J Urol2023
36442540Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.Kidney Int2023
36470342Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive?Clin Biochem2023
36103379Dietary Assessment of Lithogenic Factors in Plant-Based Meat Products.J Endourol2023
34174139Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function.Am J Transplant2022
35861573NMRpQuant: an automated software for large scale urinary total protein quantification by one-dimensional 1H NMR profiles.Bioinformatics2022
35592618Primary hyperoxaluria type 1: novel therapies at a glance.Clin Kidney J2022
35812294A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate.Kidney Int Rep2022
35386604Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series.Kidney Med2022
36465899Serum myo-inositol and valine improve metabolomic-based estimated glomerular filtration rate among kidney transplant recipients.Front Med (Lausanne)2022
36755528Application of multivariate joint modeling of longitudinal biomarkers and time-to-event data to a rare kidney stone cohort.J Clin Transl Sci2022
36316097Nuclear Magnetic Resonance Metabolomic Profiling and Urine Chemistries in Incident Kidney Stone Formers Compared with Controls.J Am Soc Nephrol2022
35933132Dietary Risk Factors for Incident and Recurrent Symptomatic Kidney Stones.Mayo Clin Proc2022
36319741GeoBioMed perspectives on kidney stone recurrence from the reactive surface area of SWL-derived particles.Sci Rep2022
35878813Progression of Chronic Kidney Disease Following Radical and Partial Nephrectomy.Urology2022
36077407Differences of Uric Acid Transporters Carrying Extracellular Vesicles in the Urine from Uric Acid and Calcium Stone Formers and Non-Stone Formers.Int J Mol Sci2022
33543760Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.Nephrol Dial Transplant2022
34918062National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories.Clin Chem2022
35041195Comparison of clinical features of pregnant and non-pregnant females with primary hyperoxaluria.J Nephrol2022
35038721Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation.Clin Chem2022
34907378The genetics of kidney stone disease and nephrocalcinosis.Nat Rev Nephrol2022
35306035Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.Am J Kidney Dis2022
35266883New therapeutics for primary hyperoxaluria type 1.Curr Opin Nephrol Hypertens2022
35294951Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors.Am J Nephrol2022
35078782Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease.Clin J Am Soc Nephrol2022
34634431End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease.Am J Kidney Dis2022
34245816Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report.Am J Kidney Dis2022
32900691Pathophysiology and Treatment of Enteric Hyperoxaluria.Clin J Am Soc Nephrol2021
36734820Back to the Future: The Role of Metabolic Studies in Therapeutic Advances.J Am Soc Nephrol2021
33912752Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.Kidney Int Rep2021
33686430Is It Time to Move On? Reexamining Race in Glomerular Filtration Rate Equations.Clin Chem2021
  • 1 - 50 of 346

Recommended Authors

Dennis G Moledina
Yale School of Medicine
Career Start Year 2013
Number of shared co-authors 15
Farrukh M Koraishy
Stony Brook University Hospital
Career Start Year 2011
Number of shared co-authors 2
Luis M Ortega
Alegheny General Hospital, Temple University School of Medicine
Career Start Year 2009
Number of shared co-authors 4
Jennifer A Schaub
University of Michigan ann arbor
Career Start Year 2008
Number of shared co-authors 15
John Danziger
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2008
Number of shared co-authors 1
John Schollum
Dunedin School of Medicine, University of Otago
Career Start Year 2008
Number of shared co-authors 0
Jamie P Dwyer
University of Utah Health
Career Start Year 2005
Number of shared co-authors 0
Martin H de Borst
University Medical Center Groningen
Career Start Year 2003
Number of shared co-authors 16
Bryan Kestenbaum
University of Washington
Career Start Year 2002
Number of shared co-authors 28
Rupam Ruchi
University of Florida
Career Start Year 2001
Number of shared co-authors 1
Amit X Garg
Western University
Career Start Year 2001
Number of shared co-authors 12
Gearoid M McMahon
Brigham and Women's Hospital, MA Harvard Medical School
Career Start Year 1999
Number of shared co-authors 19
Rajesh Mohandas
LSU Health New Orleans School of Medicine
Career Start Year 1999
Number of shared co-authors 0
Michelle R Denburg
Children's Hospital of Philadelphia
Career Start Year 1997
Number of shared co-authors 6
Michael Rudnicki
Medical University Innsbruck
Career Start Year 1997
Number of shared co-authors 4
Morgan E Grams
New York University Grossman School of Medicine
Career Start Year 1996
Number of shared co-authors 23
Abutaleb A Ejaz
University of Maryland School of Medicine
Career Start Year 1994
Number of shared co-authors 0
Andrew A House
The Lilibeth Caberto Kidney Clinical Research Unit, Western University
Career Start Year 1993
Number of shared co-authors 3
Robert J Walker
University of Otago
Career Start Year 1991
Number of shared co-authors 0
James A Tumlin
Emory University
Career Start Year 1990
Number of shared co-authors 14
Jonathan Himmelfarb
Kidney Research Institute and Division of Nephrology, University of Washington
Career Start Year 1990
Number of shared co-authors 20
Rakesh Malhotra
University of California San Diego
Career Start Year 1989
Number of shared co-authors 4
Olivier Devuyst
Institute of Physiology, University of Zurich, Cliniques Universitaires Saint-Luc
Career Start Year 1989
Number of shared co-authors 18
Julia B Lewis
Vanderbilt University Medical Center
Career Start Year 1988
Number of shared co-authors 2
Somchai Eiam-Ong
Chulalongkorn University
Career Start Year 1988
Number of shared co-authors 1
Mitchell H Rosner
University of Virginia Health
Career Start Year 1987
Number of shared co-authors 9
Gregory L Braden
Baystate Medical Center
Career Start Year 1984
Number of shared co-authors 0
Francesco Emma
Ospedale Pediatrico Bambino Gesu IRCCS
Career Start Year 1983
Number of shared co-authors 6
Zoltan H Endre
Prince of Wales Hospital and Clinical School, University of New South Wales
Career Start Year 1982
Number of shared co-authors 6
Joseph V Bonventre
Brigham & Women's Hospital
Career Start Year 1975
Number of shared co-authors 13

Collaborators

Eric J Bergstralh
Mayo Clinic
Co-authored papers 34
Felicity T Enders
Mayo Clinic
Co-authored papers 21
Kianoush B Kashani
Mayo Clinic Rochester
Co-authored papers 20
Xujian Li
Wenzhou Institute, University of Chinese Academy of Sciences
Co-authored papers 15
Erin F Barreto
Mayo Clinic
Co-authored papers 13
Stephen T Turner
Mayo Clinic
Co-authored papers 11
Jennifer A Smith
Co-authored papers 10
Sharon L R Kardia
School of Public Health, University of Michigan ann arbor
Co-authored papers 10
Lee J Melton
Mayo Clinic
Co-authored papers 9
Heather N Reich
University Health Network and University of Toronto
Co-authored papers 9
Matthias Kretzler
University of Michigan ann arbor
Co-authored papers 8
Debbie S Gipson
University of Michigan ann arbor
Co-authored papers 8
Tracy L McGregor
Alnylam Pharmaceuticals
Co-authored papers 7
Sharon G Adler
Co-authored papers 7
Jeffrey B Kopp
National Institutes of Health, National Institute of Diabetes
Co-authored papers 6
Joseph J Larson
Division of Clinical Trials and Biostatistics, Mayo Clinic
Co-authored papers 5
Charat Thongprayoon
Mayo Clinic
Co-authored papers 5
Wei Zhao
Co-authored papers 5
Laura Barisoni
Duke University
Co-authored papers 5
Vesna D Garovic
Mayo Clinic
Co-authored papers 5
Phillip J Schulte
Division of Clinical Trials and Biostatistics, Mayo Clinic
Co-authored papers 5
David M Bunk
Co-authored papers 4
Jonathan P Troost
Michigan Institute for Clinical and Health Research
Co-authored papers 4
Surendra Dasari
Mayo Clinic
Co-authored papers 3
Matthew G Sampson
Co-authored papers 3
Nicholas B Larson
Mayo Clinic
Co-authored papers 3
Ognjen Gajic
Mayo Clinic
Co-authored papers 3
Jeffrey B Hodgin
University of Michigan ann arbor
Co-authored papers 3
Ravinder J Singh
Co-authored papers 3
Vimal K Derebail
University of North Carolina at Chapel Hill
Co-authored papers 3
Release 1.2